Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Items 401–500 of 550
Rational design of adjuvants boosts cancer vaccines
Li, X., Yamazaki, T., Ebara, M., Shirahata, N., & Hanagata, N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.001 · Cited by 3
Chen, Y., 王晓楠, Chen, S., Zhang, M., Cheng, Z., Zhang, W., Liu, D., Shan, Y., Du, G., Li, W., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107555 · Cited by 3
Reprogramming of Tumor Microenvironment in Therapy
Jarosz–Biej, M., Smolarczyk, R., Cichoń, T., & Szala, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_22 · Cited by 3
Vaccination-Based Immunoprevention of Colorectal Tumors
Jackson, K., Samaddar, S., Markiewicz, M. A., & Bansal, A. K. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001808 · Cited by 3
Xu, M., Yu, J., Zhang, C., Xu, C., Wei, X., & Pu, K. (2023) · Angewandte Chemie · doi:10.1002/ange.202308362 · Cited by 3
Interleukin-12 Implication in Tumor Initiating Capacity of Colorectal Cancer Stem Cells
Xiang, L., & Liang, H. (2016) · Chemotherapy Open access · doi:10.4172/2167-7700.1000209 · Cited by 3
“Interleukin 12 (IL-12) plays an important role in creating an interconnection between the innate and adaptive immunity, such as induces the Th1-type immune response [8].”
BackgroundInnate and Adaptive Immune Responses to Cancer
Hastings, K. T., & Rausch, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_4 · Cited by 3
Cascade amplification of therapeutic payloads for cancer immunotherapy
Li, Y., Wu, J., Li, N., Wu, M., Wang, Z., Li, J., & Zhang, L. (2025) · Communications Biology · doi:10.1038/s42003-025-08735-z · Cited by 2
“Further validation of the ampli fi cation capacity of CATP was performed in a highly immune resistant mouse B16F10 melanoma model 16 via a single intratumoral 17 injection of lipid nanoparticles encapsulating CATP encoding mouse cytokine IL-12 12,18 .”
An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapies
Ishihara, J., Lee, J. K., & Priceman, S. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.018 · Cited by 2
Liu, A., Johnson, C., Niedzwiecki, D., Relation, T., Yarlagadda, S., Gajewski, T. F., & Carson, W. E. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0880 · Cited by 2
“These properties of IL12 suggested that it might be a particularly effective antitumor agent; however, administration of this cytokine as a single agent at high doses led to substantial toxicities and few clinical responses (8).”
A Literature Review of Interleukins in the Development and Treatment of Breast Cancer
Kraśnicka, W., Rybak, N., Wójcik, K., Stasiak, A., Białowąs, M., Grzegorczyk, K., Kolenda, T., Malicki, J., Marszałek, A., & Janiczek-Polewska, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083455 · Cited by 2
Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy
Oers, F. V., Katana, Z., Flumens, D., Lion, E., & Campillo-Davó, D. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102994 · Cited by 2
“160 In vivo analysis of T cells electroporated with mRNA encoding single-chain IL-12, either alone or in combination with a 4-1BB ligand, revealed that intra-tumoral injection of engineered cells enabled rejection of local and distant tumors, 161 while limiting the duration of potential adverse…”
Bonfá, G., Martino, G., Sellitto, A., Blazquez-Roman, J. L., Tedeschi, F., Rinaldi, A., Silveira, C. R. F., Piro, F. R., Caliendo, F., Melchiorri, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77730-7 · Cited by 2
“SP73 was placed upstream IL12p70, a cytokine known to enhance T cell activation and function 54 .”
Zhang, J., Wang, L., Li, S., Gao, X., & Liu, Z. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02630-x · Cited by 2
“However, later clinical studies with IL-12 did not yield satisfactory results [26, 27].”
ResultCytokine Immunotherapy for Neuroblastoma
Dowsey, M. (2023) · Science Insights · doi:10.15354/si.23.re115 · Cited by 2
Asghar, K., Bashir, S., Hassan, M. J., Farooq, A. V., Bakar, M. A., Bilal, S., Hameed, M., Mehmood, S., & Loya, A. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00310-1 · Cited by 2
“One of the lat-est approaches in immunotherapy involves using monoclonal antibodies (mAbs) that target immune checkpoint molecules, such as programmed cell death ligand-1 (PD-L1) [5–7].”
BackgroundSystemic immune response to a CD40 agonist antibody in nonhuman primates
Caudell, D. L., Dugan, G. O., Babitzki, G., Schubert, C., Braendli-Baiocco, A., Wasserman, K., Acona, G., Stern, M., Passioukov, A., Cline, J. M., et al. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae031 · Cited by 2
An, K., Li, N., Xu, X., Feng, Y., Zhao, P., & Lin, C. (2024) · ACS Applied Polymer Materials · doi:10.1021/acsapm.3c02962 · Cited by 2
Rhodes, E. R., Day, N. B., Aldrich, E. C., Shields, C. W., & Sprenger, K. G. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10722 · Cited by 2
“25,26 Murine IL-12 acts on both murine and human IL-12 receptors (IL-12R), while human IL-12 only interacts with human IL-12R.”
Zagożdżon, R., & Lasek, W. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-46906-5_1 · Cited by 2
Self-citationInterleukin-12 Gene Electrotransfer in Veterinary Oncology
Tratar, U. L., Tozon, N., Milevoj, N., Serša, G., Nemec, A., Uršič, K., & Čemažar, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-80668-2_11 · Cited by 2
Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcoma
Rademacher, M. J., Faber, M. L., Bone, K. M., Medin, J. A., & Schloemer, N. J. (2024) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2024.104898 · Cited by 2
Role of cytokine-based immunotherapy approaches in gastrointestinal cancers
ElBeblawy, R., Malla, M., & Akce, M. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.10.005 · Cited by 2
Immunomodulation of cyproheptadine hydrochloride on albino mice blood lymphocytes
Hasan, Z. Y. M., Al-Ezzy, R. M., Abdullah, J., & AL-Hamdi, B. (2017) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_23_17 · Cited by 2
“IL-12 the T cells stimulating factor secreted from macrophage and B-lymphoblast cells, possessed elevation in its level after treated the lymphocytes with different cyproheptadine doses.[19] IL-6 source is T cells, macrophages, and endothelium had target on liver, beside T and B cells acted to proliferate and produce…”
BackgroundCancer Immunology and the Evolution of Immunotherapy
Nurieva, R., Divenko, M., & Kim, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_1 · Cited by 2
CAR-T therapy in oncology and other fields of medicine
Kierasińska, A., Ciunowicz, D., Węgierska, M., Stoczyńska-Fidelus, E., & Rieske, P. (2021) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2021.106685 · Cited by 2
“Skonstruowanie komórek CAR-T wytwarzających własną IL-12 może być bezpieczniejszym sposobem na pokonanie barier hamujących działanie przeciwnowotworowe [109].”
Delivery strategies for cancer vaccines and immunoadjuvants
Graham-Gurysh, E. G., Carpenter, B. W., Beck, W. A., Varma, D. M., Vincent, B. G., Bachelder, E. M., & Ainslie, K. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00014-2 · Cited by 2
Klinman, D. M., & Shirota, H. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch7 · Cited by 2
de Castro, Í. A. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2014.tde-27112014-081410 · Cited by 2
Khan, S. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22198 · Cited by 2
Hameedat, F., Lopez-Parra, J. S., Hoogaars, W. M. H., Dijkstra, E. S. C., Huang, C., Casmil, I. C., Blakney, A. K., Olinga, P., Rothen‐Rutishauser, B., Santos, H. A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202529443 · Cited by 1
Sapsamarn, N., Methasate, A., Tanjak, P., Suwatthanarak, T., Acharayothin, O., Thanormjit, K., Swangsri, J., Parakonthun, T., Taga, T., & Chinswangwatanakul, V. (2025) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v77i7.272789 · Cited by 1
Liu, L., Lv, W., Gong, Y., Ding, Z., Song, K., Zhao, W., Liu, H., Li, S., He, W., Yin, J., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.175447 · Cited by 1
Targeting purinergic receptors in glioblastoma with nanobody-displaying AAV vectors
Jargalsaikhan, S., Schäfer, W., Zapf, N., Reetz, M., Rodríguez, D. G., Malatesta, P., Bannas, P., Dührsen, L., Mohme, M., Lamszus, K., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110955 · Cited by 1
El-Moniem, S. A., Mohammed, M. A., El-Deen, Z. M. E., & Mostafa, H. (2019) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_85_19 · Cited by 1
Swanner, J. L., Meisen, W. H., McCormack, R., Lewis, C. T., Hong, B., & Kaur, B. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_3 · Cited by 1
Kadir, R., Acosta, A., Luwi, N. M., Mohamud, R., García‐Santana, M. A., Acevedo, R., Sarmiento, M. E., & Norazmi, M. N. (2020) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_82_20 · Cited by 1
Simonaggio, A., & Marabelle, A. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(18)30397-7 · Cited by 1
The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review
Hesari, M., Attar, Z., Soltani-Shirazi, S., Keshavarzian, O., Taheri, R., Tabrizi, R., & Fouladseresht, H. (2023) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2023.0050 · Cited by 1
Development of a targeted IL-12 immunotherapy platform for B-cell lymphomas
Lee, D., Kim, D., Kim, D., Kim, N., Nam, Y. W., Lee, B. C., Song, J., & Chang, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112600 · Cited by 1
Harnessing the Potential of FAP-IL12mut TMEkine for Targeted and Enhanced Antitumor Responses
Lee, D., Kim, D., Kim, D., Kang, J., Lee, K., Lee, H., Yoon, Y., Lee, Y., Kim, N., Cho, B. C., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0125 · Cited by 1
“The TME is a dynamic dynamic and Concurrently, IL12 is a proinflammatory cytokine that has been extensively studied for its potent antitumor properties (3, 19–21).”
Medved, A., Omerzel, M., Jesenko, T., Buček, S., Serša, G., & Cemazar, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118414 · Cited by 1
KAISO: A NOVEL MEDIATOR OF INTESTINAL INFLAMMATION AND TUMORIGENESIS
Pierre, C. C. (2015) · MacSphere (McMaster University) · doi:10.71548/14905 · Cited by 1
Silva, S. G. (2015) · Americanae (AECID Library) · Cited by 1
AVALIAÇÃO DO EFEITO DO ÁCIDO GÁLICO NO TRATAMENTO DE CÉLULAS DE HEPATOCARCINOMA HEPG2
Lima, K. G. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Bio-Engineering Vaccinia Viruses for Increased Oncolytic Potential
Pelin, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-24148 · Cited by 1
Markel, J. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7770 · Cited by 1
Espinoza‐Sánchez, N. A., Chimal-Ramírez, G. K., Mantilla, A., & Fuentes‐Pananá, E. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00856 · Cited by 1
STING ACTIVATING PARTICLES FOR CANCER IMMUNOTHERAPY
Cheng, N. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ncwm-eb07 · Cited by 1
Interleukin 12-Secreting Chimeric Antigen Receptor T Cells And Cancer Immunotherapy
Chang, P. (2016) · eCommons (Cornell University) · Cited by 1
La souris humanisée : modèle d'étude de l'immunothérapie anti-cancer
Rochère, P. D. L. (2018) · theses.fr (ABES) · doi:10.70675/62c63415zab1az40e4z8c1fz0b5580505c4f · Cited by 1
Reversing Breast Cancer-Induced Immune Suppression
Beury, D. W., & Ostrand‐Rosenberg, S. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada573503
Antitumor Effects of IL-12 in Preclinical Studies
Lasek, W., & Jakóbisiak, M. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-46906-5_2
Self-citationThe role of IL-15 in response to rhinovirus infections
Jayaraman, A. (2012) · Spiral (Imperial College London) · doi:10.25560/9775
Alkayyal, A. A. (2016) · uO Research (University of Ottawa) · doi:10.20381/ruor-557
“The term cancer immunoediting refers to the immune system’s ability to both protect the host and sculpt the tumor [8].”
BackgroundCell-based IL-12 Immunotherapy In A Transgenic Murine Breast Cancer Model
Mielnik, M. (2017) · TSpace (University of Toronto)
Immunomodulation with Adjuvants and Cytokines
Kim, D. W., & Diab, A. K. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch9
Reshaping the Immunosuppressive Tumor Microenvironment: The Fusion Protein Strategy
Wei, Y. (2016) · Cell & Cellular Life Sciences Journal · doi:10.23880/cclsj-16000102
“Recent studies agree that IL-12 plays a central role in antitumor immune surveillance and the elimination of IL-12 production is one of the key factors affecting the anti-to pro-tumor transition in tumor microenvironment [16].”
BackgroundSmith, S. G. (2017) · NCSU Libraries Repository (North Carolina State University Libraries)
Characterising distinct mechanisms of interleukin-12-mediated tumour suppression
Burkhard, S. (2015) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-164465
Scott, A. N. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-j47p-0v68
Naif, H. M. (2017) · Journal of Contemporary Medical Sciences · doi:10.22317/jcms.12201703
Derivado semi-sintético cumarínico 2h-1-benzopiran-2-ona, 7- preniloxi com potencial antitumoral
da Cruz, R. M. D. (2016) · Americanae (AECID Library)
He, Z. (2020) · AIP conference proceedings · doi:10.1063/5.0000308
Rahmani, S., Burke, D., Jarvis, P., Orsi, N. M., Cummings, M., Turvill, S., & Howell, S. J. (2020) · Acta Scientific Medical Sciences · doi:10.31080/asms.2020.04.0795
Matias, B. D. G. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Hölldorfer, C. L.-M. (2020) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-21889
Najmuddin, S. U. F. S., & Faruq, S. U. (2019) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Immune response, inflammation pathway gene polymorphisms, and the risk of cervical cancer
Verma, H. K., Farran, B., & Bhaskar, L. V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00011-3
Tumor microenvironment-responsive nanogel for therapeutic delivery of interleukin-12
Arhontoulis, D. C., & Cheng, H. (2016) · iDEA - Drexel University Institutional Repository · doi:10.17918/etd-6834
Development and Characterization of Protease ActivatedCytokine Fusion Proteins
Skrombolas, D. (2015) · UR Research (University of Rochester)
Role of CD47 in innate and adaptive immune response during viral infection
Cham, L. B. (2020) · DuEPublico (University of Duisburg-Essen) · doi:10.17185/duepublico/72699
Agarwal, Y., Wittrup, K. D., & Irvine, D. J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.738
Valencia, A. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2021.tde-14122021-133005
Evaluation of the circulating IL-12 in women with breast cancer in Erbil city
Daham, Z. I. A., & Darogha, S. N. (2021) · Diyala Journal for Pure Science · doi:10.24237/djps.1801.573b
Eletrogeneterapia com IFN-Beta em modelo murino de melanoma
da Luz, J. C. D. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2021.tde-10112021-164626
Daniels, G. A. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_11
Psoriasis Biologic Agents in Special Populations
Thatiparthi, A., Martin, A., Liu, J., Han, G., & Wu, J. J. (2022) · Updates in clinical dermatology · doi:10.1007/978-3-030-92938-1_11
Asara, J. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735744949.793560218
Faculty Opinions recommendation of Cancer immunotherapy beyond immune checkpoint inhibitors.
Olive, D. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732456067.793574154
Cytokines, Interferons, and Hematopoietic Growth Factors
Epperla, N., Hanel, W. G., & Talpaz, M. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm064.pub2
Battula, S. K., Papastoitsis, G., Kaufman, H. L., Wittrup, K. D., & Schmidt, M. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1076
“can promote innate and adaptive anti-cancer immunity, but its clinical development has been limited by toxicity when delivered systemically.(1) Intratumoral (IT) administration can expand”
BackgroundRelationship of SNPs (rs3212227) in IL-12 with Gynecological and Breast Cancer*
Jebur, M. H., Alshibly, I. K., & Alrubaee, B. J. (1970) · Journal of Biotechnology Research Center · doi:10.24126/jobrc.2021.15.2.615
Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B. D., et al. (2023) · doi:10.1158/1535-7163.c.6542815
Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B. D., et al. (2023) · doi:10.1158/1535-7163.c.6542815.v1
Nirschl, C. J., Brodkin, H. R., Domonkos, C., Dwyer, C. J., Hicklin, D. J., Ismail, N. S., Seidel‐Dugan, C., Steiner, P., Steuert, Z., Sullivan, J. M., et al. (2023) · doi:10.1158/2326-6066.c.6653474
Kasahara, S., Kashiwagi, M., Inubushi, T., Sugauchi, A., Deyong, W., Kurioka, K., Miyagawa, K., Matsuda, T., Seki, S., Kogo, M., et al. (2026) · Oral Diseases · doi:10.1111/odi.70399
Advances in Cancer Gene Therapy: Strategies, Delivery Methods, and Challenges
Lepland, A., & Veiman, K.-L. (2025) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-4374-7_6
Immunocytokines based on IL-12 for cancer therapy: Enhancing efficacy and reducing toxicity
Beloki, U., Salaberry, L., Covo-Vergara, Á., Ortuño-Moya, C., Silva-Pilipich, N., & Smerdou, C. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.03.003
Immunotherapy and Tumor Resistance to Immune-Mediated Control and Elimination
Monnot, G., & Romero, P. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00235-0
Nakatake, M., Itadani, H., Kurosaki, H., & Nakamura, T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.055
Wang, S., Zhang, M., Lin, L., Dong, J., Wang, X., Liu, X., Zhang, S., Liu, G., & Kang, X. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.171773
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.